Abstract Library

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4426 A case of giant neuroendocrine tumour of unknown primary site

Introduction: The liver is a common site for metastatic neuroendocrine tumours. NETs primary to the liver are rare, and it is difficult to determine whether a neuroendocrine tumour in the liver is primary or metastatic in patients in whom no tumour has been found elsewhere.

Conference:

Presenting Author: Yingmei T

Authors: Jieting D, Yanping Z, Yingmei T, Rongfang T, Yan W,

Keywords: neuroendocrine tumour, primary hepatic neuroendocrine tumour, metastatic,

#4422 A case report of an undifferentiated neuroendocrine carcinoma with an unknown primary site

Introduction: In the situation where the primary lesion remains unknown, high-grade poorly differentiated neuroendocrine carcinoma typically shows extensive metastasis at the time of clinical visit. Common metastatic sites include the liver, bones, lungs and brain, and the prognosis is extremely poor.

Conference:

Presenting Author:

Authors: Lv J, Tang Y,

Keywords: poorly differentiated neuroendocrine carcinoma, unknown primary origin,

#3776 Long-term effects of peptide receptor radionuclide therapy (PRRT) used as first-line treatment of GEP-NET – A single centre experience

Introduction: Peptide receptor radionuclide therapy (PRRT) is a well-recognized treatment option for inoperable/metastatic somatostatin receptor-positive neuroendocrine tumors (NET) currently according to guidelines used as second or third line of treatment.

Conference:

Presenting Author:

Authors: Opalinska M, Sowa-Staszczak A, Kurzyńska A, Morawiec-Sławek K, Olearska H,

Keywords: PRRT, first-line treatment, outcome, GEP-NET, NET,

#3538 A challenging diagnosis of a neuroendocrine tumor of unknown origin associated with primary aldosteronism

Introduction: Neuroendocrine tumors (NETs) of unknown primary site account for 10 to 14 percent of all neuroendocrine neoplasms.

Conference:

Presenting Author: Ciobanu O

Authors: Ciobanu O, Martin S, Fica S,

Keywords: neuroendocrine tumor, unknown origin, primary hyperaldosteronism, challenging diagnosis,